DIM Sartorius Stedim Biotech SA

Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.69 euros per share to Annual Shareholders’ Meeting

Sartorius Stedim Biotech SA / Key word(s): Dividend
Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.69 euros per share to Annual Shareholders’ Meeting

07-Feb-2025 / 15:57 CET/CEST


 

Aubagne, February 7, 2025

Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.69 euros per share to Annual Shareholders’ Meeting
 
  • Cécile Dussart and Christopher Nowers nominated for election to the Board of Directors at the upcoming Shareholders’ Meeting

The Board of Directors of Sartorius Stedim Biotech S.A. resolved at its meeting to submit a proposal to the combined Annual Shareholders’ Meeting on March 25, 2025, to pay a dividend of 0.69 euros per share for fiscal 2024, the same amount as for the previous year. If approved, the total distributed profit would be 67.1 million euros. The dividend will be paid as from April 4, 2025.

The Board of Directors also approved the decision to submit to the Annual Shareholders’ Meeting the 2024 results of Sartorius Stedim Biotech which had already been published on a preliminary basis on January 28, 2025.

While the mandate of one member of the Board of Directors will expire at the closing of the 2025 Annual Shareholders’ Meeting, the Board decided upon proposal of the Remuneration and Nomination Committee to suggest Cécile Dussart and Christopher Nowers to the Annual Shareholders’ Meeting as new Board candidates.

Doctor of Pharmacy Cécile Dussart serves as a Board Member and ESG committee chair of CDMO and API provider EuroAPI S.A. and is a member of the Advisory Commitee at the talent intelligence platform Neobrain. Prior, she held various management positions at the Swiss listed dermatology group Galderma and at the pharmaceutical companies Roche and Sanofi.

Biochemist Christopher Nowers, CEO of the cell therapy company ONK Therapeutics, held several senior leadership roles in the biopharma industry including Kite Pharma, Bristol-Myers Squibb, and Amgen. He is also a member of the Advisory Board at CAR T cell company Autolus Therapeutics.

The following four members will be proposed to the AGM for renewal: Pascale Boissel, René Fáber, Lothar Kappich and Joachim Kreuzburg. Henri Riey, member of the Board since 2007 will no longer be available for a further term and will retire from the Board at the end of the Annual Shareholders’ Meeting. Already at this point, the Board would like to thank him very much for his valuable contributions and expertise that he brought to the company during his many years of service. 


This media release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. Sartorius Stedim Biotech shall not assume any liability for the correctness of this release. The original French press release is the legally binding version.

 
Financial calendar
February 17, 2025                   Publication of Annual Report
March 25, 2025                         Annual Shareholders’ Meeting
April 16, 2025                            Publication of the first quarter results January to March 2025
July 22, 2025                              Publication of the half-year results January to June 2025
October 16, 2025                    Publication of the nine-month results January to September 2025


A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros, according to preliminary figures. Currently, more than 9,900 employees are working for customers around the globe.

Visit our and follow us on .


Contact
Leona Malorny
Head of External Communications
7


 

Attachment

File:


Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


Language: English
Issuer: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone:
E-mail:
Internet: -stedim.com
ISIN: FR0013154002
EQS News ID: 2083349

 
End of Announcement - EQS News Service

2083349  07-Feb-2025 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2083349&application_name=news&site_id=research_pool~~~9efe1c65-8ece-4ff7-9608-f21c8e0a38a3
EN
07/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sartorius Stedim Biotech SA

Chaima Ferrandon ... (+3)
  • Chaima Ferrandon
  • Christian Arnold
  • Sven Edelfelt
AKRBF AKER BP ASA
LHN HOLCIM AG
FP TOTAL SE
HEIA HEINEKEN NV
PUB PUBLICIS GROUPE SA
GET GETLINK SE
SGO COMPAGNIE DE SAINT-GOBAIN SA
O2D TELEFONICA DEUTSCHLAND HOLDING AG
EDEN EDENRED SA
IPN IPSEN SA
EQNR EQUINOR ASA
ETL EUTELSAT COMMUNICATIONS SA
BT.A BT GROUP PLC
SESGL SES SA FDR (CLASS A)
DG VINCI SA
PROX PROXIMUS SA DE DROIT PUBLIC
GALP GALP ENERGIA SGPS SA CLASS B
NK IMERYS SA
SLB.N SCHLUMBERGER NV
KPN ROYAL KPN NV
ORA ORANGE SA
VCT VICAT-CIMENTS VICAT SA
TKA TELEKOM AUSTRIA AG
GTT GAZTRANSPORT & TECHNIGAZ SA
FGR EIFFAGE SA
ERIC B TELEFONAKTIEBOLAGET LM ERICSSON CLASS B
SBMO SBM OFFSHORE NV
EN BOUYGUES SA
GBF BILFINGER SE
SRT3 SARTORIUS AG PREF
AGS AGEAS SA/NV
UTDI UNITED INTERNET AG
OMV OMV AG
AMUN AMUNDI SA
GAMA GAMMA COMMUNICATIONS
RAND RANDSTAD NV
ENI ENI S.P.A.
GEBN GEBERIT AG
HEI HEIDELBERGCEMENT AG
DTE DEUTSCHE TELEKOM AG
P2F PETROFAC LIMITED
IMPN IMPLENIA AG
REP REPSOL SA
CRG CRH PLC
TUB TUBACEX S.A.
SOC SUBSEA 7 S.A.
PKN POLSKI KONCERN NAFTOWY ORLEN S.A.
SBO SCHOELLER-BLECKMANN OILFIELD EQUIPMENT AG
DIM SARTORIUS STEDIM BIOTECH SA
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
TIT TELECOM ITALIA S.P.A.
WBD WEBUILD S.P.A.
INX IMCD N.V.
CLNX CELLNEX TELECOM S.A.
FNTN FREENET AG
TRE TECNICAS REUNIDAS SA
RIO RIO TINTO PLC
TEC TECHNIPFMC PLC
SNG SOCIETATEA NATIONALA DE GAZE NATURALE ROMGAZ SA
SNP PETROM S.A.
ASML ASML HOLDING NV
BP. BP P.L.C.
MOL MOL HUNGARIAN OIL & GAS PLC CLASS A
VOD VODAFONE GROUP PLC
OBEL ORANGE BELGIUM SA
TEF TELEFONICA SA
NFN NFON AG
DRI 1&1 DRILLISCH AG
SIK SIKA AG
FDJ LA FRANCAISE DES JEUX SA
VK VALLOUREC SA
TE TECHNIP ENERGIES NV
FUR FUGRO NV
SHEL SHELL PLC
SPM SAIPEM S.P.A.
TEN TENARIS S.A.
VIRI VIRIDIEN
Chaima Ferrandon ... (+3)
  • Chaima Ferrandon
  • Christian Arnold
  • Sven Edelfelt
AKRBF AKER BP ASA
LHN HOLCIM AG
FP TOTAL SE
HEIA HEINEKEN NV
PUB PUBLICIS GROUPE SA
GET GETLINK SE
SGO COMPAGNIE DE SAINT-GOBAIN SA
O2D TELEFONICA DEUTSCHLAND HOLDING AG
EDEN EDENRED SA
IPN IPSEN SA
EQNR EQUINOR ASA
ETL EUTELSAT COMMUNICATIONS SA
BT.A BT GROUP PLC
SESGL SES SA FDR (CLASS A)
DG VINCI SA
PROX PROXIMUS SA DE DROIT PUBLIC
GALP GALP ENERGIA SGPS SA CLASS B
NK IMERYS SA
SLB.N SCHLUMBERGER NV
KPN ROYAL KPN NV
ORA ORANGE SA
VCT VICAT-CIMENTS VICAT SA
TKA TELEKOM AUSTRIA AG
GTT GAZTRANSPORT & TECHNIGAZ SA
FGR EIFFAGE SA
ERIC B TELEFONAKTIEBOLAGET LM ERICSSON CLASS B
SBMO SBM OFFSHORE NV
EN BOUYGUES SA
GBF BILFINGER SE
SRT3 SARTORIUS AG PREF
AGS AGEAS SA/NV
UTDI UNITED INTERNET AG
OMV OMV AG
AMUN AMUNDI SA
GAMA GAMMA COMMUNICATIONS
RAND RANDSTAD NV
ENI ENI S.P.A.
GEBN GEBERIT AG
HEI HEIDELBERGCEMENT AG
DTE DEUTSCHE TELEKOM AG
P2F PETROFAC LIMITED
IMPN IMPLENIA AG
REP REPSOL SA
CRG CRH PLC
TUB TUBACEX S.A.
SOC SUBSEA 7 S.A.
PKN POLSKI KONCERN NAFTOWY ORLEN S.A.
SBO SCHOELLER-BLECKMANN OILFIELD EQUIPMENT AG
DIM SARTORIUS STEDIM BIOTECH SA
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
TIT TELECOM ITALIA S.P.A.
WBD WEBUILD S.P.A.
INX IMCD N.V.
CLNX CELLNEX TELECOM S.A.
FNTN FREENET AG
TRE TECNICAS REUNIDAS SA
RIO RIO TINTO PLC
TEC TECHNIPFMC PLC
SNG SOCIETATEA NATIONALA DE GAZE NATURALE ROMGAZ SA
SNP PETROM S.A.
ASML ASML HOLDING NV
BP. BP P.L.C.
MOL MOL HUNGARIAN OIL & GAS PLC CLASS A
VOD VODAFONE GROUP PLC
OBEL ORANGE BELGIUM SA
TEF TELEFONICA SA
NFN NFON AG
DRI 1&1 DRILLISCH AG
SIK SIKA AG
FDJ LA FRANCAISE DES JEUX SA
VK VALLOUREC SA
TE TECHNIP ENERGIES NV
FUR FUGRO NV
SHEL SHELL PLC
SPM SAIPEM S.P.A.
TEN TENARIS S.A.
VIRI VIRIDIEN
 PRESS RELEASE

Résolutions de l’Assemblée générale annuelle mixte des actionnaires de...

Sartorius Stedim Biotech SA / Mot-clé(s) : Assemblée générale Résolutions de l’Assemblée générale annuelle mixte des actionnaires de Sartorius Stedim Biotech S.A. 25-Mars-2025 / 15:35 CET/CEST Aubagne, le 25 mars 2025 Résolutions de l’Assemblée générale annuelle mixte des actionnaires de Sartorius Stedim Biotech S.A.Lors de l'Assemblée générale annuelle mixte de Sartorius Stedim Biotech S.A. qui s'est tenue aujourd'hui, les actionnaires à une large majorité ont donné décharge à tous les administrateurs.Les actionnaires ont élu Cécile Dussart et Christopher Nowers en tant que nouve...

 PRESS RELEASE

Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius ...

Sartorius Stedim Biotech SA / Key word(s): AGM/EGM Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A. 25-March-2025 / 15:35 CET/CEST Aubagne, France | March 25, 2025 Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.At today’s combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A., shareholders granted discharge to all Directors by a large majority.The shareholders elected Cécile Dussart and Christopher Nowers as new Board Members. To ensure staggering of office terms, both were appointed...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch